Dual drug delivery systems based on natural and synthetic polymer particles for isoniazid and rifampicin vehiculization
; Ferrero, Francisco J. ; Turino, Ludmila Noelia
; Karp, Federico
; López, Marcela A. ; Luna, Julio Alberto
; Mengatto, Luciano Nicolas 
Otros responsables
Fecha
10/2024
Editorial
John Wiley & Sons
Revista
Journal of Applied Polymer Science
Título del libro
Nombre del evento
Fecha del evento
Institución organizadora
ISSN
0021-8995
eISSN
ISBN
Idioma
Inglés
Tipo del evento
Clasificación temática
Palabras clave
Resumen
The purpose of this work is the design and characterization of novel systemsbased on micro and nanoparticles prepared from poly(lactic-co-glycolic) acid(PLGA), chitosan (CHT) and gelatin (GEL) for compartmentalization and dualrelease of rifampicin and isoniazid. The emulsion/evaporation method isemployed for the preparation of PLGA based microparticles and nanoparticles.CHT and GEL are used for the preparation of microparticles by spray-drying.Entrapment efficiencies are in the range of 35%–73% and 5%–29% for rifampicinand isoniazid in PLGA microparticles, respectively. For isoniazidGEL:CHT particles the entrapment efficiencies are within 82%–100%. Isoniazidshows a complete release at acid condition from GEL:CHT particles, whilerifampicin release is maintained from GEL:CHT particles or displays anslightly increase from PLGA particles during buffer conditions. Antimycobacterialactivity experiments show that the formulations present the ability toinhibit the bacterial growth in comparison with a control culture withouttreatment. Rifampicin PLGA and isoniazid GEL:CHT microparticles could beused for the preparation of a dual drug delivery system with each antibiotic ina single particulate compartment. GEL:CHT microparticles containing free isoniazidand rifampicin PLGA nanoparticles are a novel two compartment deliverysystem.
Colecciones
Aprobación
Revisión
Complementado por
Referenciado por
Licencia Creative Commons
Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa
